MAPK1 and amyotrophic lateral sclerosis: In summary, this study demonstrates that the combination therapy of VPA and ALA exerts therapeutic effects in ALS by modulating multiple targets and pathways, with the synergistic effects primarily involving TNF, EGFR, MAPK1, and MAPK8.